Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2011 1
2012 3
2013 1
2014 4
2015 11
2016 13
2017 12
2018 8
2019 13
2020 7
2021 6
2022 3
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

71 results

Results by year

Filters applied: . Clear all
Page 1
Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial.
Lee JD, Nunes EV Jr, Novo P, Bachrach K, Bailey GL, Bhatt S, Farkas S, Fishman M, Gauthier P, Hodgkins CC, King J, Lindblad R, Liu D, Matthews AG, May J, Peavy KM, Ross S, Salazar D, Schkolnik P, Shmueli-Blumberg D, Stablein D, Subramaniam G, Rotrosen J. Lee JD, et al. Lancet. 2018 Jan 27;391(10118):309-318. doi: 10.1016/S0140-6736(17)32812-X. Epub 2017 Nov 14. Lancet. 2018. PMID: 29150198 Free PMC article. Clinical Trial.
Opioid Use Disorders.
Sharma B, Bruner A, Barnett G, Fishman M. Sharma B, et al. Child Adolesc Psychiatr Clin N Am. 2016 Jul;25(3):473-87. doi: 10.1016/j.chc.2016.03.002. Epub 2016 Apr 9. Child Adolesc Psychiatr Clin N Am. 2016. PMID: 27338968 Free PMC article. Review.
Nurse Care Management for Opioid Use Disorder Treatment: The PROUD Cluster Randomized Clinical Trial.
Wartko PD, Bobb JF, Boudreau DM, Matthews AG, McCormack J, Lee AK, Qiu H, Yu O, Hyun N, Idu AE, Campbell CI, Saxon AJ, Liu DS, Altschuler A, Samet JH, Labelle CT, Zare-Mehrjerdi M, Stotts AL, Braciszewski JM, Murphy MT, Dryden D, Arnsten JH, Cunningham CO, Horigian VE, Szapocznik J, Glass JE, Caldeiro RM, Phillips RC, Shea M, Bart G, Schwartz RP, McNeely J, Liebschutz JM, Tsui JI, Merrill JO, Lapham GT, Addis M, Bradley KA; PROUD Trial Collaborators; Ghiroli MM, Hamilton LK, Hu Y, LaHue JS, Loree AM, Murphy SM, Northrup TF, Shmueli-Blumberg D, Silva AJ, Weinstein ZM, Wong MT, Burganowski RP. Wartko PD, et al. JAMA Intern Med. 2023 Dec 1;183(12):1343-1354. doi: 10.1001/jamainternmed.2023.5701. JAMA Intern Med. 2023. PMID: 37902748
Identifying substance misuse in primary care: TAPS Tool compared to the WHO ASSIST.
Schwartz RP, McNeely J, Wu LT, Sharma G, Wahle A, Cushing C, Nordeck CD, Sharma A, O'Grady KE, Gryczynski J, Mitchell SG, Ali RL, Marsden J, Subramaniam GA. Schwartz RP, et al. J Subst Abuse Treat. 2017 May;76:69-76. doi: 10.1016/j.jsat.2017.01.013. Epub 2017 Jan 31. J Subst Abuse Treat. 2017. PMID: 28159441 Free PMC article.
Documented opioid use disorder and its treatment in primary care patients across six U.S. health systems.
Boudreau DM, Lapham G, Johnson EA, Bobb JF, Matthews AG, McCormack J, Liu D, Campbell CI, Rossom RC, Binswanger IA, Yarborough BJ, Arnsten JH, Cunningham CO, Glass JE, Murphy MT, Zare M, Hechter RC, Ahmedani B, Braciszewski JM, Horigian VE, Szapocznik J, Samet JH, Saxon AJ, Schwartz RP, Bradley KA. Boudreau DM, et al. J Subst Abuse Treat. 2020 Mar;112S:41-48. doi: 10.1016/j.jsat.2020.02.001. J Subst Abuse Treat. 2020. PMID: 32220410 Free PMC article.
71 results